Mammalian Cell Culture Media Patents: Leaders & Trends 2026
- Concentrated but not locked up. The leader holds 711 records, yet the top 5 combined account for only 15.4% of the 12,825 records in scope — a long tail of single- and few-filing entrants sits beneath a handful of large incumbents.
- Filing has cooled from its 2017 peak. Filings peaked at 356 in 2017; on the most recent complete years, 2021's 239 fell to 147 in 2024, a 38% drop over that span.
- Claim space is dense in the core, thinner at the edges. 94.0% of records sit in C12N (microorganisms & genetic engineering), but classes like C07H (sugars & nucleic acids) cover only 12.0% — a much thinner layer of prior art.
Filing growth compares 2021 (239 records) with 2024 (147) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 12,825 records in scope (CR5), not by the ranked leaders only.
What this landscape covers
This landscape draws on 12,825 published records filed against IPC classes covering microorganism culture, cell culture apparatus, and enzyme/DNA-based measurement (C12N5/00, C12M3/00, C12Q1/02), filtered to records that combine mammalian, animal or CHO cell culture terms with formulation-relevant concepts: amino acid supplementation, growth factors, lipid supplements, glucose and osmolality control, and serum replacement. The scope spans 2015 through the 2026-07-31 cut-off, though publication lag means the most recent one to two years are undercounted.
The dataset favours large biologics manufacturers and legacy cell-line developers, reflecting where recombinant protein production has historically concentrated its media and feed IP. Receiving-office data shows the United States and Europe as the dominant filing venues, with WIPO PCT filings indicating a meaningful share of applicants pursuing multi-jurisdiction protection from the outset.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trend and technology composition
Two views of the same 12,825-record corpus: how filing volume has moved year over year, and which IPC subclasses carry the claim density.
A 2017 peak followed by a multi-year pullback
Filings hit 356 in 2017, the high point of the series. Using the most recent years that can be treated as complete, 2021's 239 filings fell to 147 by 2024 — a 38% decline over three years. Because publication lags filing by roughly 18 months, 2025 and 2026 figures will fill in further and should not be read as a continued slide.
Core biology dominates; formulation-adjacent classes are thinner
C12N (microorganisms & genetic engineering) appears in 94.0% of the 12,825 records, with C07K (peptides & proteins) and A61K (medicinal preparations) each near 48.9%. C07H (sugars & nucleic acids), at 12.0%, is the thinnest major class tracked here — a signal of where formulation claims are less crowded relative to the core biology layer.
Shares are the percentage of the 12,825 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Mammalian Cell Culture Media Formulation with Eureka
This page is one run against one query. Ask Eureka your own question about mammalian cell culture media formulation and every answer comes back with the patent numbers behind it.
Try EurekaThe documents anchoring this field
US8663945B2 — Methods of producing anti-TNF-alpha antibodies in mammalian cell culture
The invention describes improved methods and compositions for producing a recombinant protein, e.g., an antibody, in mammalian cell culture. In addition, the invention provides improved cell culture media, including improved production media, feed solutions, and combination feeds, which may be used to improve protein productivity in mammalian cell culture.Filed by AbbVie Inc., published 2014-03-04 — illustrative of how media and feed composition claims are bundled with a specific production process rather than filed as standalone formulation patents.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US5122469A | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins | 3,304 |
| 2 | US4560655A | Serum-free cell culture medium and process for making same | 2,896 |
| 3 | WO1987000195A1 | Animal cell culture | 2,582 |
| 4 | WO1990003430A1 | Cell culture medium for enhanced cell growth, culture longevity and product expression | 2,397 |
| 5 | WO1990007936A1 | Recombinant therapies for infection and hyperproliferative disorders | 1,132 |
| 6 | US8895308B1 | Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation | 996 |
| 7 | US6689558B2 | Cells for drug discovery | 968 |
| 8 | WO1998030679A1 | Embryonic stem cell serum replacement | 870 |
| 9 | US8889418B2 | Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation | 858 |
| 10 | EP0307247A2 | A method for culturing recombinant cells | 733 |
Ranked by citation count within this corpus; older foundational filings accumulate citations simply by being in the field longer, so treat this as a signal of influence rather than of current commercial relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers mean for a filing decision
Three findings from the corpus that matter more for strategy than the raw ranking does.
The leader is large, the field is not locked up
The leading assignee holds 711 records, but the top 5 combined reach only 15.4% of all 12,825 records in scope, and the top 10 just 22.9%. That leaves the majority of filings distributed across a long tail — new entrants are not filing into a field owned by two or three players.
Volume has pulled back from its 2017 high
Filings peaked at 356 in 2017 and, across the most recent complete years, fell from 239 in 2021 to 147 in 2024 — a 38% decline. That is a genuine multi-year pullback in complete-year data, not an artefact of publication lag, though the very latest years will still revise upward.
Sugar and nucleic-acid classes are the thinnest layer
Against a corpus where C12N reaches 94.0% of records, C07H (sugars & nucleic acids) sits at just 12.0% — the lowest coverage among the major classes tracked. Formulation work that leans on carbohydrate or nucleic-acid components is filed into comparatively less crowded claim space than the core cell-biology classes.
US and EPO dominate, PCT signals global intent
The United States leads receiving offices with 3,181 filings, followed by Europe at 2,350 and WIPO PCT at 1,634. The PCT volume indicates a substantial share of applicants are pursuing multi-jurisdiction protection from filing, rather than expanding territory later.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to mammalian cell culture media formulation, with the prior art for and against each one.
Who is filing, and who has slowed down
The ranked leaders include large biologics manufacturers and cell-line technology licensors. Recent-year momentum data shows several of the largest historical filers pulling back sharply in the latest tracked year — read this alongside the 18-month publication lag rather than as a sign the field is closing.
A single incumbent well ahead of the field
The top-ranked assignee holds 711 records against a fifth-place figure of 211 and a tenth-place figure of 167 — a steep drop-off after the leader, then a more gradual taper through the ranked leaders.
Even large historical filers are slowing in the latest year
Several of the assignees with the deepest filing histories show sharp year-on-year declines in the most recent tracked year, including drops of -75% and -80% at individual assignees and filings falling to zero at others. Given the 18-month publication lag, some of this is measurement artefact rather than a real stop in R&D.
Co-filing is limited and concentrated around one filer
Only 10 co-assignee pairs appear in the corpus, and the strongest pairings cluster around a single assignee working with named individual inventors. Formal cross-company co-assignment is the exception in this field, not the norm.
| Assignee | Recent year | YoY |
|---|---|---|
| Genentech, Inc. | 2 | 0% |
| Regeneron Pharmaceuticals, Inc. | 2 | -80% |
| Life Technologies Corporation | 1 | -75% |
| Amgen Inc. | 0 | -100% |
| Human Genome Sciences, Inc. | 0 | — |
| Incyte Corporation | 0 | — |
| Wyeth LLC | 0 | — |
| Technion Research & Development Foundation Ltd. | 0 | — |
Where to take this next
The ranking and the composition data point to specific next steps depending on whether the goal is freedom-to-operate or a new filing.
Check freedom-to-operate against the densest classes
C12N and C07K/A61K cover roughly half or more of all records in scope, so any new formulation claim touching core cell-biology or peptide composition should be checked against this density before drafting.
Run a freedom-to-operate check in EurekaScope claims toward the thinner adjacent classes
C07H's 12.0% coverage and the under-claimed sub-areas identified here suggest where a narrower, more defensible first claim is more achievable than in the crowded core.
Explore white space in EurekaTrack momentum shifts among large historical filers
Several long-standing filers show sharp year-on-year drops in the latest tracked year; watching whether this persists past the publication-lag window matters for competitive positioning.
Set up assignee monitoring in EurekaCommon questions about this landscape
The dataset's leading assignee holds 711 records, well ahead of the field, with the fifth-ranked assignee at 211 and the tenth at 167. However, the top 5 combined account for only 15.4% of the 12,825 records in scope, and the top 10 for 22.9%, so the field is far from a two- or three-way contest. A long tail of assignees with a handful of filings each makes up the majority of the corpus.
Filings peaked at 356 in 2017 and, across the most recent years that can be treated as complete, fell from 239 in 2021 to 147 in 2024 — a 38% decline. That is a real multi-year pullback in complete-year data. The most recent one to two years in the raw trend appear lower still, but that reflects roughly 18 months of publication lag rather than a further collapse in filing activity.
C12N (microorganisms and genetic engineering) covers 94.0% of the 12,825 records in scope, making it by far the densest class. C07K (peptides & proteins) and A61K (medicinal preparations) each cover about 48.9%, and C12Q (enzyme/DNA measurement) covers 38.0%. Because a single record can carry multiple IPC classes, these percentages add up to well over 100% and should not be summed.
The thinnest major class tracked in this corpus is C07H (sugars & nucleic acids) at 12.0% of records, well below the 94.0% coverage of the core C12N class. Sub-areas such as carbohydrate-based osmolality control, chemically defined lipid supplement blends and real-time glucose feedback sit adjacent to the dense core and carry comparatively less claim density, making them worth checking before assuming a formulation idea is already blocked.
US8663945B2, assigned to AbbVie, claims methods and compositions for producing recombinant proteins, including antibodies, in mammalian cell culture, bundled with specific production media, feed solutions and combination feeds. It illustrates a common pattern in this field: media and feed composition claims filed alongside a specific production process rather than as a standalone formulation patent. Anyone designing a similar production-plus-feed workflow should review the specific feed and combination-feed claims rather than assume a generic media patent controls the space.
Research Mammalian Cell Culture Media Formulation in depth with Eureka
Go past this page: query the whole mammalian cell culture media formulation corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.